融捷健康科技股份有限公司 2024 年度 内部控制审计报告 目 录 内部控制审计报告 1-2 中证天通会计师事务所（特殊普通合伙） 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 内部控制审计报告 中证天通(2025) 证审字 36100005 号 融捷健康科技股份有限公司全体股东： 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业 内部控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 性是得润电子公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性 发表审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外， 由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的 程度降低，根据内部控制审计结果推测未来内部控制的有 ...

融捷健康科技股份有限公司 2024 年度 财务报表之审计报告 目 录 | 一、审计报告 | 1-4 | | --- | --- | | 二、已审公司财务报表 | | | 1.合并资产负债表 | 1-2 | | 2.母公司资产负债表 | 3-4 | | 3.合并及公司利润表 | 5 | | 4.母公司利润表 | 6 | | 5.合并现金流量表 | 7 | | 6.母公司现金流量表 | 8 | | 7.合并所有者（股东）权益变动表 | 9-10 | | 8.母公司所有者（股东）权益变动表 | 11-12 | | 9.财务报表附注 | 13-81 | 中证天通会计师事务所（特殊普通合伙） 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 审 计 报 告 中证天通（2025）证审字 36100004 号 融捷健康科技股份有限公司全体股东： 一、审计意见 我们审计了后附的融捷健康科技股份有限公司（以下简称"融捷健康公司"）财 务报表，包 ...

关于融捷健康科技股份有限公司 非经营性资金占用及其他 关联资金往来的专项说明 目 录 | 关于融捷健康科技股份有限公司非经营性资金占 | 1-2 | | --- | --- | | 用及其他关联资金往来的专项说明 | | | 融捷健康科技股份有限公司 2024 年度非经营性 | 1-2 | | 资金占用及其他关联资金往来情况汇总表 | | 中证天通会计师事务所（特殊普通合伙） 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 关于融捷健康科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况的专项说明 中证天通（2025）证审字 36100004 号-1 融捷健康科技股份有限公司全体股东： 我们接受融捷健康科技股份有限公司（以下简称"融捷健康公司"）委托， 根据中国注册会计师执业准则审计了融捷健康公司 2024 年 12 月 31 日的 合并及母公司资产负债表，2024 年度合并及母公司利润表、合并及母公 司 ...

融捷健康科技股份有限公司 独立董事黄华敏 2024 年度述职报告 本人作为融捷健康科技股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《公司法》、《证券法》、《深圳证券交易所创业板上市 公司规范运作指引》、《公司章程》、《公司独立董事制度》等相关法律法规 的规定和要求，忠实履行独立董事职责，切实发挥独立董事作用，积极参加公 司股东大会、董事会，认真审议各项议案，并发表独立意见，维护公司整体利 益和股东合法权益。 现就本人 2024 年度履行独立董事职责情况汇报如下： 一、出席会议情况 | 董事会召开次数 | 4 | 应出席次数 | 4 | | --- | --- | --- | --- | | 亲自出席会议次数 | 4 | 委托出席次数 | 0 | | 是否连续两次未亲自出席会议 | | 否 | | | 股东大会召开次数 | 2 | 出席次数 | 2 | 2024 年度我本着勤勉务实和诚信负责的原则，所有议案经过客观谨慎的思 考，均投了赞成票，没有投反对票和弃权票。在召开会议之前，我认真获取做 出决议所需要的资料和信息，在会议上，我认真审议每个议案，积极参与讨论 并提出合理化建议，为会议做出科 ...

本人作为融捷健康科技股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《公司法》、《证券法》、《深圳证券交易所创业板上市 公司规范运作指引》、《公司章程》、《公司独立董事制度》等相关法律法规 的规定和要求，忠实履行独立董事职责，切实发挥独立董事作用，积极参加公 司股东大会、董事会，认真审议各项议案，并发表独立意见，维护公司整体利 益和股东合法权益。 融捷健康科技股份有限公司 独立董事蒋基路 2024 年度述职报告 现就本人 2024 年度履行独立董事职责情况汇报如下： 一、出席会议情况 | 董事会召开次数 | 4 | 应出席次数 | 4 | | --- | --- | --- | --- | | 亲自出席会议次数 | 4 | 委托出席次数 | 0 | | 是否连续两次未亲自出席会议 | | 否 | | | 股东大会召开次数 | 2 | 出席次数 | 2 | 2024 年度我本着勤勉务实和诚信负责的原则，所有议案经过客观谨慎的思 考，均投了赞成票，没有投反对票和弃权票。在召开会议之前，我认真获取做 出决议所需要的资料和信息，在会议上，我认真审议每个议案，积极参与讨论 并提出合理化建议，为会议做出科 ...

融捷健康科技股份有限公司董事会专项意见 融捷健康科技股份有限公司 董事会关于独立董事 2024 年度保持独立性情况的专项意见 根据证监会《上市公司独立董事管理办法》、《深圳证券交易所股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等要求，融捷健康科技股份有限公司（以下简称"公司"）董事会，就公司在任 独立董事蒋基路女士、黄华敏先生的独立性情况进行评估并出具如下专项意见： 董事会认为公司全体独立董事均具备胜任独立董事岗位的资格。独立董事及 其配偶、父母、子女、主要社会关系未在公司或公司附属企业任职，未在公司及 主要股东或其各自的附属企业任职，未与公司存在重大的持股关系，与公司以及 主要股东或其各自的附属企业之间不存在重大业务往来关系或提供财务、法律、 咨询、保荐等服务关系。 综上，公司在任独立董事不存在任何妨碍其进行独立客观判断的关系，不存 在影响独立董事独立性的情况，符合《上市公司独立董事管理办法》、《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立 董事独立性的相关要求。 融捷健康科技股份有限公司 董事会 2025 年 4 月 22 ...

Financial Performance - The basic earnings per share increased by 100% from 0.0300 yuan in 2023 to 0.0600 yuan in 2024 [1] - Operating revenue rose by 30.25%, reaching 6.89 billion yuan compared to 5.29 billion yuan in the previous year [1] - Net profit saw a significant increase of 74.07%, amounting to 0.47 billion yuan, up from 0.27 billion yuan in 2023 [1] - The return on equity improved to 4.50%, a 69.81% increase from 2.65% in the previous year [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 21,756.62 million shares, accounting for 27.08% of the circulating shares, with a decrease of 527.70 million shares compared to the previous period [1] - Rongjie Investment Holding Group Co., Ltd. remains the largest shareholder with 11,691.23 million shares, unchanged from the previous report [2] - New entrants to the top ten shareholders include Mi Ying with 4,000.00 million shares and Zhang Pingping with 1,028.76 million shares [2] - Notable exits from the top ten shareholders include Shenzhen Jinghuan Technology Co., Ltd. with 4,000.00 million shares and Jin Daoming with 1,157.65 million shares [2] Dividend Distribution - No specific details on dividend distribution plans were provided in the documents [1][2]

Financial Performance - The company's operating revenue for 2024 reached ¥688,791,514.90, representing a 30.10% increase compared to ¥529,447,502.52 in 2023[22] - The net profit attributable to shareholders for 2024 was ¥46,854,048.65, a significant increase of 76.26% from ¥26,582,643.81 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥39,375,335.61, up 56.33% from ¥25,186,787.21 in 2023[22] - The total assets at the end of 2024 were ¥1,303,178,909.04, reflecting a 6.68% increase from ¥1,221,559,067.16 at the end of 2023[22] - The net assets attributable to shareholders increased by 4.80% to ¥1,065,690,539.17, compared to ¥1,016,847,716.12 at the end of 2023[22] - The basic earnings per share for 2024 were ¥0.06, doubling from ¥0.03 in 2023[22] - The weighted average return on equity for 2024 was 4.50%, an increase of 1.85 percentage points from 2.65% in 2023[22] Cash Flow and Investments - The net cash flow from operating activities decreased by 42.25% to ¥51,056,974.83, down from ¥88,411,728.33 in 2023[22] - Operating cash inflow increased by 27.71% to ¥704,260,892.49 in 2024, primarily due to increased sales collections[62] - Operating cash outflow rose by 41.06% to ¥653,203,917.66, mainly due to increased inventory levels corresponding to higher sales[62] - Investment cash inflow slightly decreased by 1.02% to ¥508,268,850.44, while investment cash outflow decreased by 9.79% to ¥487,696,883.30[60] - Net cash flow from investment activities improved significantly by 175.78% to ¥20,571,967.14, attributed to the redemption of financial products[63] - The company reported a net increase in cash and cash equivalents of ¥61,172,552.88, a 20.30% increase compared to the previous year[60] Revenue Sources and Product Performance - The infrared therapy sauna series contributed CNY 488.37 million, accounting for 70.90% of total revenue, with a year-on-year growth of 27.85%[50] - The company's revenue from the far-infrared therapy series reached ¥488,366,756.97, with a gross margin of 44.09%, showing a year-on-year revenue increase of 27.85%[52] - Sales volume of the far-infrared therapy series increased by 35.91% to 60,761 units, while production volume rose by 42.97% to 61,884 units, driven by increased market orders[54] - The portable sauna series experienced a significant sales volume increase of 172.26% to 97,610 units, attributed to a substantial rise in orders for newly developed products[54] Research and Development - The company has intensified its R&D efforts, leading to improved product quality and market competitiveness, with successful certifications from multiple international standards[37] - The company plans to increase R&D investment to enhance product competitiveness and promote technological innovation[88] - The company’s R&D expenses increased by 29.14% to ¥11,697,173.96, indicating a commitment to enhancing product development[59] - R&D investment amounted to ¥11,697,173.96 in 2024, representing 1.70% of operating revenue, a slight decrease from 1.71% in 2023[60] - The number of R&D personnel increased by 17.24% from 58 in 2023 to 68 in 2024, with a proportion of 14.05% of total employees[60] Market Strategy and Expansion - The company operates in the health industry, which is experiencing growth driven by aging population trends and increasing health awareness, positioning it for future expansion[31] - The company is focusing on optimizing its market layout to ensure stable growth in a dynamic international market environment[37] - The company is actively exploring new growth points and business models to adapt to the complex economic environment[33] - Market expansion plans include entering two new regions, which are projected to increase market share by 10%[113] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB for potential deals[114] Corporate Governance and Compliance - The company emphasizes the importance of maintaining a transparent and timely information disclosure system[90] - The company will enhance internal control management and governance levels to ensure compliance and protect investor rights[90] - The board of directors consists of six members, including two independent directors, ensuring compliance with governance standards[97] - The company has established a transparent performance evaluation and incentive mechanism for its management team[100] - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[100] Employee and Management Structure - The total number of employees at the end of the reporting period is 484, including 390 from the parent company and 94 from major subsidiaries[128] - The professional composition includes 318 production personnel, 41 sales personnel, 68 technical personnel, 20 financial personnel, and 37 administrative personnel[128] - The company has a performance bonus system linked to annual business objectives, effectively motivating employee engagement and creativity[129] - Annual training plans are developed based on departmental needs and company strategies, enhancing the skills of management and technical personnel[130] Risk Management - The management has outlined potential risks and countermeasures in the report, emphasizing the importance of investor awareness regarding future plans and forecasts[4] - The company recognizes international market risks due to uncertainties in U.S. tariff policies and plans to diversify market strategies to mitigate these risks[90] - Raw material costs constitute a significant portion of operating costs, and the company will adjust procurement strategies and inventory levels to mitigate the impact of price fluctuations[91] Legal and Regulatory Matters - The company has a pending lawsuit involving a claim of ¥4,000,000 (approximately $570,000) against Anhui Lejin Junze Health Management Co., Ltd. for loan repayment[149] - The court ruled that the defendant must repay the principal amount of ¥4,000,000 and interest, with the interest calculated at an annual rate of 5%[149] - The company has not faced any penalties from securities regulatory authorities for its directors and supervisors in the past three years[118] - There were no significant related party transactions reported during the period, including asset acquisitions or joint investments[153][154] Audit and Financial Reporting - The audit opinion for the financial statements is a standard unqualified opinion, indicating fair representation of the company's financial status as of December 31, 2024[186] - The financial statements were audited by Zhongzheng Tiantong Accounting Firm, with the audit report signed on April 21, 2025[186] - The audit procedures included evaluating the effectiveness of internal controls related to revenue recognition and analyzing revenue growth by product category and customer[192][193]

Core Viewpoint - Rongjie Health (300247) announced a profit forecast for 2024, expecting a net profit between 42 million to 48 million yuan, representing a year-on-year growth of 58.00% to 80.57% [1] Group 1: Financial Performance - The company anticipates a significant increase in net profit for 2024, with projections indicating a growth range of 58.00% to 80.57% [1] - The stock closed at 3.46 yuan, down 1.14%, with a trading volume of 41.21 million yuan and a turnover rate of 1.48% [1] - Over the past five days, the stock has decreased by 2.54% [1] Group 2: Market Reaction - Historical data shows that 69.38% of stocks with a profit forecast increase of over 50% experienced a price increase on the announcement day, with 22 stocks hitting the daily limit [1] - In the five days following the announcement, 72.73% of these stocks saw price increases [1] Group 3: Capital Flow - The stock experienced a net inflow of 2.6454 million yuan in principal funds today, while there was a net outflow of 2.2714 million yuan over the past five days [1]

Financial Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 42 million and 48 million yuan, representing a year-on-year increase of 58.00% to 80.57% compared to 26.58 million yuan in the previous year[4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 34 million and 40 million yuan, indicating a year-on-year growth of 34.99% to 58.81% from 25.19 million yuan in the previous year[4]. Market Expansion - The company is actively expanding into overseas markets, contributing to an increase in operating income compared to the previous year[6]. Financial Reporting - The fair value of investment properties has decreased, leading to a discrepancy between the growth rates of net profit attributable to shareholders and net profit after deducting non-recurring gains and losses[6]. - The financial data presented is preliminary and has not been audited by the accounting firm, but there are no significant discrepancies in financial data discussions with the accounting firm[5].